A Phase II Study to Assess Befotertinib and Icotinib as First-Line Treatment in Patients With Locally Advanced or Metastatic NSCLC and Uncommon EGFR Mutation(IcomBine, GASTO-10114)
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Befotertinib (Primary) ; Icotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IcomBine
Most Recent Events
- 29 Jul 2024 New trial record